english.prescrire.org > Spotlight > Archives : 2019 > Pembrolizumab (Keytruda°) in urothelial carcinoma

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2019 : 1 | 30 | 60

In the January issue of Prescrire International: Pembrolizumab (Keytruda°) in urothelial carcinoma

FREE DOWNLOAD In this month's sample review: Prescrire's editors rate pembrolizumab (Keytruda°) "Possibly helpful" in certain patients with locally advanced or metastatic urothelial carcinoma.
Full text available for free download.

Summary

  • Pembrolizumab (Keytruda°) has been authorised in the EU for use in patients with locally advanced or metastatic urothelial carcinoma, after failure of platinum-based chemotherapy or when cisplatin-containing chemotherapy cannot be used.
     
  •  POSSIBLY HELPFUL  In a non-blinded comparative randomised trial after failure of platinum-containing chemotherapy, pembrolizumab prolonged survival by about 3 months compared with taxane- or vinflunine-containing chemotherapy. Its adverse effects were different and less frequent.
     

Full text available for free download.

 ©Prescrire 1 January 2019

"Pembrolizumab (Keytruda°) in urothelial carcinoma" Prescrire Int 2019; 28 (200): 9. (Pdf, free).

Share Share on Facebook Share on Twitter

 

Share
Partager sur Facebook Partager sur Twitter

 
Download the full review
Pdf, free
 
Prescrire's rating:
Prescrire's rating
 POSSIBLY HELPFUL